PK150 (Sorafenib Analog)

CHF 25.00
In stock
AG-CR1-0162-M0011 mgCHF 25.00
AG-CR1-0162-M0055 mgCHF 50.00
AG-CR1-0162-M02525 mgCHF 135.00
More Information
Product Details
Synonyms Antibiotic PK150; 1-(4-Chloro-3-(trifluoromethyl)phenyl)-3-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)urea
Product Type Chemical
Properties
Formula

C15H8ClF5N2O3

MW 394.7
CAS 2165324-62-7
Purity Chemicals ≥98% (HPLC)
Appearance White to off-white solid.
Solubility Soluble in DMSO (25mg/ml).
Identity Determined by 1H-NMR.
InChi Key SHPYXCLUNMOJOB-UHFFFAOYSA-N
Smiles O=C(NC1=CC(OC(F)(F)O2)=C2C=C1)NC3=CC=C(Cl)C(C(F)(F)F)=C3
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Analog of the anticancer drug sorafenib.
  • PK150 is a potent antibiotic. It shows oral bioavailability and antibacterial activity against several pathogenic strains at submicromolar concentrations. PK150 inhibits Gram-positive Methicillin-sensitive S. aureus (MSSA), Methicillin-resistant S. aureus (MRSA), Vancomycin intermediate S. aureus (VISA) with MICs of 0.3, 0.3-1, 0.3 µM, respectively.
  • PK150 did not induce in vitro resistance and shows oral bioavailability and in vivo efficacy. The mode of action includes the interference with menaquinone biosynthesis by inhibiting demethylmenaquinone methyltransferase and the stimulation of protein secretion by altering the activity of signal peptidase IB.
Product References
  1. Repurposing human kinase inhibitors to create an antibiotic active against drug-resistant Staphylococcus aureus, persisters and biofilms: P. Le, et al.; Nat. Chem. 12, 145 (2020)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.